BioCentury
ARTICLE | Top Story

Affiris claims disease modification with Alzheimer's placebo

June 5, 2014 12:51 AM UTC

Affiris AG (Vienna, Austria) said the placebo in its Phase II trial of its AD02 vaccine against beta amyloid "is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients." The company said the placebo -- now called AD04 and "a strong focus" for Affiris -- stabilized cognition and function for over 18 months in 47% of patients. ...